Home > Search Clinical Trials > Skin - Psoriasis
Clinical Trials: Skin - Psoriasis
IRB No. 18-194J-1 (Dr. Bruce Strober, PI): Skin Microbiome of Inverse Psoriasis
Psoriasis is a disfiguring and disabling skin disease that affects as high as one out of 25 Americans, but the root cause is still unknown. Inverse psoriasis is a form of the disease that only affects the skin folds of the body. It causes painful, shiny, red rashes in very sensitive areas like the genitals, groin and underneath the breasts. Past studies have identified particular microbes that live within these skin folds. Collectively, the genes of these microbes are called the skin microbiome. We believe that the skin microbiome at the skin fold sites may have something to do with what causes inverse psoriasis. Currently, there have been no studies on the skin microbiome and inverse psoriasis. Therefore, we plan to be the first to identify and characterize the skin microbiome in people who have inverse psoriasis. We plan to recruit three groups of volunteers: plaque psoriatics 1) with and 2) without inverse psoriasis and 3) healthy people to determine if there are differences in their microbes that may be contributing to their inverse psoriasis lesions. Volunteers in group 2 (without inverse psoriasis) who develop Inverse Psoriasis during the course of the study will be asked to re-enroll in the study into group 4. We will prospectively track the inverse microbiome as these patients receivesystemic biologic therapies, to determine if these therapies alter the microbiome during effective treatment.In this effort, we hope to better understand psoriasis and ultimately provide substantial improvement to the quality of life for these patients.
IRB No. 18-050-1 (Dr. Jun Lu, PI): Corrona Psoriasis Registry
The Corrona Psoriasis Registry is a prospective, multicenter, observational registry that will compare the safety of approved psoriasis therapies in patients across the nation who are actively being treated with these medications by dermatologists. Patients must have been started on, or have been switched to a biologic psoriasis medication within the 12 months preceeding enrollment. Adverse events of special interest, including malignancy, will be followed for all patients.